NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

OLMA

Olema Pharmaceuticals Inc

Jul 02 • 04:00PM ET

4.54

Dollar change +0.17
Percentage change 3.89	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD VRTX REGN BIIB ONC INCY NBIX EXEL ACAD

| Held by: VTI IWM VXF IWN IBB VTWO SCHA DFAS VHT IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.95	Insider Own	23.83%	Shs Outstand	68.33M	Perf Week	-4.42%
Market Cap	310.63M	Forward P/E	-	EPS next Y	-2.18	Insider Trans	1.87%	Shs Float	52.12M	Perf Month	3.77%
Enterprise Value	-80.93M	PEG	-	EPS next Q	-0.43	Inst Own	78.35%	Short Float	12.86%	Perf Quarter	35.93%
Income	-128.89M	P/S	-	EPS this Y	17.14%	Inst Trans	-10.51%	Short Ratio	7.17	Perf Half Y	-26.18%
Sales	0.00M	P/B	0.81	EPS next Y	-19.37%	ROA	-38.29%	Short Interest	6.70M	Perf YTD	-22.13%
Book/sh	5.61	P/C	0.79	EPS next 5Y	6.64%	ROE	-41.59%	52W High	16.62 -72.68%	Perf Year	-58.04%
Cash/sh	5.74	P/FCF	-	EPS past 3/5Y	-7.01% -83.00%	ROIC	-33.60%	52W Low	2.86 58.74%	Perf 3Y	4.37%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.73% 8.03%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	3.31%	Oper. Margin	-	ATR (14)	0.35	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	15.22	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	52.03	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	15.22	EPS Q/Q	36.17%	SMA20	5.34%	Beta	1.91	Target Price	25.20
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-2.90%	Rel Volume	0.66	Prev Close	4.37
Employees	96	LT Debt/Eq	0.00	Earnings	May 13 AMC	SMA200	-34.10%	Avg Volume	934.11K	Price	4.54
IPO	Nov 19, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	25.77% -	Trades		Volume	613,166	Change	3.89%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-24	Initiated	Goldman	Buy	$24
Jan-30-24	Initiated	Citigroup	Buy	$20
Jul-21-23	Initiated	Oppenheimer	Outperform	$21
May-05-23	Initiated	CapitalOne	Overweight	$16
Feb-22-23	Initiated	Credit Suisse	Outperform	$12
Jul-06-22	Resumed	Canaccord Genuity	Buy	$16
Jun-09-22	Upgrade	H.C. Wainwright	Neutral → Buy	$12
Feb-28-22	Initiated	H.C. Wainwright	Neutral
Dec-07-21	Resumed	Cowen	Outperform
Dec-14-20	Initiated	JP Morgan	Overweight	$52
Dec-14-20	Initiated	Jefferies	Buy	$70
Dec-14-20	Initiated	Cowen	Outperform
Dec-14-20	Initiated	Canaccord Genuity	Buy	$60

Show Previous Ratings

Jul-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.43%
May-28-25 07:00AM	Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting (GlobeNewswire)
May-21-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
09:55AM	Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High? (Zacks)
04:01PM	Loading…
May-13-25 04:01PM	Olema Oncology Reports First Quarter 2025 Financial and Operating Results (GlobeNewswire)
May-09-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.24%
Apr-25-25 01:00PM	Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025 (GlobeNewswire)
Apr-24-25 09:55AM	Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a Bet (Zacks)
Apr-10-25 09:35AM	After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA) (Zacks) +8.25%
Apr-08-25 04:25PM	Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market (Seeking Alpha)
Apr-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-25-25 04:31PM	Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting (GlobeNewswire)
Mar-18-25 04:01PM	Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results (GlobeNewswire) -6.97%
04:30PM	Loading…
Mar-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-25 04:30PM	Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 07:00AM	Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Feb-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.46%
Feb-03-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-03-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.75% -6.62%
Jan-02-25 07:00AM	Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-24 07:00AM	Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-09-24 07:00AM	Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor (GlobeNewswire) -9.67%
Dec-03-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:17AM	Novartis and Olema expand alliance with $250m to boost breast cancer trials (Pharmaceutical Technology)
Dec-02-24 07:00AM	Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement (GlobeNewswire)
Nov-25-24 05:30PM	Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium (GlobeNewswire) +9.09%
Nov-24-24 07:27PM	Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors (PR Newswire)
Nov-12-24 04:01PM	Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -9.28%
07:01AM	Loading…
Nov-06-24 07:01AM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 04:44PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-23-24 07:00AM	Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024 (GlobeNewswire)
Oct-09-24 07:00AM	Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-02-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-24 04:49PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-21-24 07:00AM	Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-06-24 04:02PM	Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -9.90%
Aug-02-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -14.22%
Aug-01-24 08:50AM	Recent Price Trend in Olema Pharmaceuticals (OLMA) is Your Friend, Here's Why (Zacks)
Jul-02-24 04:29PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.55%
Jun-14-24 07:05PM	TruBridge, Evans Bancorp, and More Stocks See Action From Activist Investors (Barrons.com)
Jun-04-24 04:28PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +18.96%
May-28-24 07:03AM	Olema Oncology to Participate in Upcoming Investor Conferences in June (GlobeNewswire)
May-15-24 07:01AM	Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress (GlobeNewswire)
May-08-24 10:58PM	OLMA Stock Earnings: Olema Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace) -9.31%
04:02PM	Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:02AM	Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress (GlobeNewswire)
May-03-24 12:15PM	Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 (PR Newswire) +5.96%
May-02-24 04:37PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-01-24 07:02AM	Olema Oncology to Participate in Upcoming Investor Conferences in May (GlobeNewswire)
Apr-08-24 04:30PM	Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference (GlobeNewswire) +5.33%
Apr-05-24 12:16AM	Goldman Sachs Predicts Over 120% Rally for These 2 Strong Buy Stocks (TipRanks)
Apr-02-24 04:29PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-11-24 04:03PM	Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -6.62%
Mar-06-24 07:03AM	Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors (GlobeNewswire)
Mar-04-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.01%
Feb-06-24 07:01AM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-02-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-22-24 10:54AM	15 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-08-24 08:12AM	Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate (GlobeNewswire)
Jan-02-24 04:01PM	Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-23 10:59AM	Hedge Fund and Insider Trading News: 3G Capital, Elliott Management, Harbor Capital, Three Arrows Capital, Nucor Corporation (NUE), Olema Pharmaceuticals, Inc. (OLMA), and More (Insider Monkey)
Dec-05-23 12:27PM	Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies (GlobeNewswire) -15.34%
Dec-04-23 04:29PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-01-23 09:30AM	Top Stocks for December 2023 (Investopedia)
Nov-28-23 05:10PM	Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS) (GlobeNewswire)
Nov-27-23 12:54PM	Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why (Zacks) -5.79%
11:32AM	This Small Cap Is My Stock Pick, as the Market Shakes Its Hangover (TheStreet.com)
Nov-22-23 09:00AM	Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued. (Investor's Business Daily)
Nov-07-23 04:02PM	Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +10.43%
Nov-02-23 04:32PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.35% +5.40%
Nov-01-23 04:27PM	Olema Oncology to Participate in Upcoming Investor Conferences in November (GlobeNewswire) +12.42%
Oct-30-23 08:50AM	Olema Pharmaceuticals, Inc. (OLMA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Oct-26-23 10:33AM	12 Best Performing NASDAQ Stocks in 2023 (Insider Monkey)
Oct-22-23 02:55AM	Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant (GlobeNewswire)
Oct-20-23 01:15PM	5 Best Performing Biotech Stocks in 2023 (Insider Monkey)
Oct-17-23 07:01AM	Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors (GlobeNewswire)
Oct-16-23 07:02AM	Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress (GlobeNewswire) -16.55%
Oct-12-23 07:01AM	Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity (GlobeNewswire)
Oct-11-23 09:55AM	Wall Street Analysts Believe Olema Pharmaceuticals, Inc. (OLMA) Could Rally 76.47%: Here's is How to Trade (Zacks) -5.18%
08:50AM	Here's Why Momentum in Olema Pharmaceuticals, Inc. (OLMA) Should Keep going (Zacks)
Oct-10-23 07:00AM	Olema Oncology Announces Expansion of Collaboration Agreement with Novartis (GlobeNewswire)
Oct-03-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-27-23 09:24PM	7 Strong Buy Biotech Stocks to Rejuvenate Your Portfolio (InvestorPlace)
Sep-25-23 09:55AM	Does Olema Pharmaceuticals, Inc. (OLMA) Have the Potential to Rally 80.29% as Wall Street Analysts Expect? (Zacks)
08:50AM	Here's What Could Help Olema Pharmaceuticals, Inc. (OLMA) Maintain Its Recent Price Strength (Zacks)
Sep-20-23 07:29AM	Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-15-23 01:09PM	BIOTECHNOLOGY VALUE FUND L P Acquires Stake in Olema Pharmaceuticals Inc (GuruFocus.com) +6.09%
Sep-14-23 11:02PM	Insider Buying: BIOTECHNOLOGY VALUE FUND L P Acquires 1,505,932 Shares of Olema Pharmaceuticals Inc (GuruFocus.com)
Sep-08-23 12:00PM	What Makes Olema Pharmaceuticals, Inc. (OLMA) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Predict a 91.97% Upside in Olema Pharmaceuticals, Inc. (OLMA): Here's What You Should Know (Zacks)
Sep-07-23 04:02PM	The 7 Best Small-Cap Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-06-23 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.02%
Sep-05-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +19.51%
07:30AM	Olema Oncology Announces Combined Financing for Up to $180 Million (GlobeNewswire)
Aug-08-23 04:03PM	Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +12.05%
08:23AM	Here's Why We're Watching Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation (Simply Wall St.)
Aug-02-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.05%
Aug-01-23 08:00AM	Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bain Capital Life Sciences Inv	10% Owner	Jan 08 '25	Buy	5.76	300,000	1,727,370	7,800,000	Jan 13 04:34 PM
Graham G. Walmsley	Director	Dec 17 '24	Sale	6.75	700,761	4,730,137	0	Dec 17 07:52 PM
Zojwalla Naseem	CHIEF MEDICAL OFFICER	Dec 16 '24	Option Exercise	4.87	14,000	68,180	129,509	Dec 17 07:29 PM
Logos Opportunities Fund I LP	Affiliate	Dec 13 '24	Proposed Sale	6.75	700,761	4,730,137		Dec 13 04:37 PM
Harmon Cyrus	Director	Dec 10 '24	Sale	9.37	8,256	77,359	772,277	Dec 11 07:56 PM
Harmon Cyrus	Director	Dec 11 '24	Sale	8.68	8,137	70,597	764,140	Dec 11 07:56 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Dec 11 '24	Sale	8.68	13,614	118,116	598,333	Dec 11 07:56 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Dec 10 '24	Sale	9.38	12,452	116,800	611,947	Dec 11 07:56 PM
Zojwalla Naseem	CHIEF MEDICAL OFFICER	Dec 11 '24	Sale	8.68	14,522	125,994	115,509	Dec 11 07:54 PM
Zojwalla Naseem	CHIEF MEDICAL OFFICER	Dec 10 '24	Sale	9.37	13,283	124,462	130,031	Dec 11 07:54 PM
Kovacs Shane William Charles	CH. OPERATING & FINANCIAL OFF.	Dec 11 '24	Sale	8.68	18,356	159,259	543,549	Dec 11 07:53 PM
Kovacs Shane William Charles	CH. OPERATING & FINANCIAL OFF.	Dec 10 '24	Sale	9.37	16,803	157,444	561,905	Dec 11 07:53 PM
Bohen Sean	PRESIDENT AND CEO	Dec 11 '24	Sale	8.68	57,174	496,052	241,662	Dec 11 07:52 PM
Bohen Sean	PRESIDENT AND CEO	Dec 10 '24	Sale	9.37	52,328	490,313	298,836	Dec 11 07:52 PM
Harmon Cyrus	Director	Dec 11 '24	Proposed Sale	8.68	8,137	70,635		Dec 11 05:19 PM
Kovacs Shane William Charles	Officer	Dec 11 '24	Proposed Sale	8.68	18,356	159,345		Dec 11 05:04 PM
Myles David C.	Officer	Dec 11 '24	Proposed Sale	8.68	13,614	118,180		Dec 11 04:52 PM
Zojwalla Naseem	Officer	Dec 11 '24	Proposed Sale	8.68	14,522	126,062		Dec 11 04:33 PM
Bohen Sean	Officer	Dec 11 '24	Proposed Sale	8.68	57,174	496,322		Dec 11 04:27 PM
Bohen Sean	Officer	Dec 10 '24	Proposed Sale	9.37	52,328	490,241		Dec 10 03:23 PM
Myles David C.	Officer	Dec 10 '24	Proposed Sale	9.38	12,452	116,748		Dec 10 02:48 PM
Harmon Cyrus	Director	Dec 10 '24	Proposed Sale	9.37	8,256	77,367		Dec 10 02:38 PM
Kovacs Shane William Charles	Officer	Dec 10 '24	Proposed Sale	9.37	16,803	157,426		Dec 10 02:21 PM
Zojwalla Naseem	Officer	Dec 10 '24	Proposed Sale	9.37	13,283	124,517		Dec 10 02:14 PM
Kovacs Shane William Charles	Ch. Operating & Financial Off.	Nov 15 '24	Option Exercise	7.02	25,000	175,500	510,458	Nov 18 06:00 AM
Paradigm Biocapital Advisors L	10% Owner	Aug 01 '24	Sale	14.91	2,400,000	35,796,000	783,118	Aug 05 04:30 PM
Harmon Cyrus	Director	Jul 29 '24	Sale	15.58	4,066	63,348	752,217	Jul 31 05:15 PM
Harmon Cyrus	Director	Jul 30 '24	Sale	15.55	934	14,524	751,283	Jul 31 05:15 PM
Harmon Cyrus	Director	Jul 30 '24	Proposed Sale	15.55	934	14,526		Jul 30 04:15 PM
Harmon Cyrus	Director	Jul 29 '24	Proposed Sale	15.58	4,066	63,352		Jul 29 04:23 PM
Harmon Cyrus	Director	Jul 11 '24	Sale	12.26	5,000	61,300	756,283	Jul 12 05:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OLMA

Olema Pharmaceuticals Inc

Upgrade your FINVIZ experience